Starting from this background, the aim of the present study was to determine whether a treatment with 4MP once weekly alters the development of non‐obese MASLD in mice and if this is related to changes in JNK activation as well as to determine further associated molecular mechanisms. The gene discussed is MAPK8; the disease is metabolic dysfunction-associated steatotic liver disease.